S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Taro Pharmaceutical Industries Stock Forecast, Price & News

+0.19 (+0.30 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,129 shs
Average Volume24,402 shs
Market Capitalization$2.43 billion
P/E Ratio84.20
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Taro Pharmaceutical Industries logo

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.94 out of 5 stars

Medical Sector

641st out of 1,351 stocks

Pharmaceutical Preparations Industry

311th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

Is Taro Pharmaceutical Industries a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Taro Pharmaceutical Industries stock.
View analyst ratings for Taro Pharmaceutical Industries
or view top-rated stocks.

What stocks does MarketBeat like better than Taro Pharmaceutical Industries?

Wall Street analysts have given Taro Pharmaceutical Industries a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Taro Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Taro Pharmaceutical Industries

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Tuesday, July, 27th. The company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.84 by $0.25. The company had revenue of $147.11 million for the quarter, compared to the consensus estimate of $137.20 million. Taro Pharmaceutical Industries had a net margin of 5.10% and a trailing twelve-month return on equity of 8.81%.
View Taro Pharmaceutical Industries' earnings history

How has Taro Pharmaceutical Industries' stock been impacted by COVID-19?

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TARO shares have decreased by 0.7% and is now trading at $63.99.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TARO?

1 equities research analysts have issued 1-year target prices for Taro Pharmaceutical Industries' stock. Their forecasts range from $82.00 to $82.00. On average, they expect Taro Pharmaceutical Industries' stock price to reach $82.00 in the next year. This suggests a possible upside of 28.1% from the stock's current price.
View analysts' price targets for Taro Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Uday Vijaykumar Baldota, Chief Executive Officer & Director
  • Itamar Karsenti, Vice President & Head-Operations
  • Avi Avramoff, Vice President & Head-Research & Development
  • Richard Glaze, Vice President & Head-Information Technology
  • Michele Visosky, Vice President & Head-Human Resources

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries CEO Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among Taro Pharmaceutical Industries' employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.94%), FMR LLC (1.43%), Krensavage Asset Management LLC (1.43%), Dimensional Fund Advisors LP (1.38%), Brandes Investment Partners LP (0.67%) and Invesco Ltd. (0.47%).

Which institutional investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, FMR LLC, Citigroup Inc., BlackRock Inc., Renaissance Technologies LLC, Royal Bank of Canada, Canada Pension Plan Investment Board, and Northern Trust Corp.

Which institutional investors are buying Taro Pharmaceutical Industries stock?

TARO stock was acquired by a variety of institutional investors in the last quarter, including Murchinson Ltd., Morgan Stanley, Morgan Stanley, Dimensional Fund Advisors LP, Hotchkis & Wiley Capital Management LLC, Invesco Ltd., Parametric Portfolio Associates LLC, and American Century Companies Inc..

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $63.99.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries has a market capitalization of $2.43 billion and generates $548.97 million in revenue each year. The company earns $-386,650,000.00 in net income (profit) each year or $3.70 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

Taro Pharmaceutical Industries employs 1,417 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is www.taro.com.

Where are Taro Pharmaceutical Industries' headquarters?

Taro Pharmaceutical Industries is headquartered at 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at (724) 847-5700 or via email at [email protected].

This page was last updated on 9/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.